## Selective Methylation of the Ninhydrin-Phenol Adducts with I<sub>2</sub> in MeOH

Jeong Eun Na, Saravanan GowriSankar, Sangku Lee,<sup>†</sup> and Jae Nyoung Kim<sup>\*</sup>

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea <sup>†</sup>Korea Research Institute of Bioscience and Biotechnology, 52 Oun, Yusong, Daejeon 305-333, Korea Received December 23, 2003

Key Words : Selective methylation, Ninhydrin, Phenol, Iodine, Methanol

The formation of ninhydrin-phenol adducts and chemical transformations of them have been studied by us and other groups.<sup>1,2</sup> The adducts can be easily prepared from ninhydrin (1) and phenols 2 in acetic acid in good vields.<sup>1,2</sup> The structure of the ninhydrin-phenol adduct 3 is benzo[b]indeno[2,1-d]furanone skeleton in CDCl<sub>3</sub>. However, the adduct 3 existed in equilibrium with its ring-opened form 3' in DMSO- $d_b$  (Scheme 1). The structure can be easily confirmed from the <sup>1</sup>H NMR spectrum. For the cyclic form **3a**, as an example, the protons at the ninhydrin moiety appeared as t, d, t, and d at around 7.49-8.02 ppm in CDCl<sub>3</sub> (a in Figure 1). Whereas, 3a and 3a' existed in a ratio of 65:35 in the <sup>1</sup>H NMR spectrum in DMSO-d<sub>0</sub> (b in Figure 1). The four protons of the ninhydrin molety of **3a'** appeared as a singlet apparently at 8.00 ppm due to the symmetric nature of the compound of 3a' (Figure 1). The characteristic peaks of **3a** (t, d, t, d) remained in about 65% with slightly different chemical shifts.

We have published the alkylation of the ninhydrin-phenol adduct **3** in DMF in the presence of  $K_2CO_3$  (Scheme 1).<sup>1a</sup> As shown in Scheme 1, the formation of **5** is the major pathway. Ring-opened component **3'** existed to some extent in DMF as in DMSO-d<sub>b</sub> and underwent the alkylation at the more acidic phenolic OH via **A**. As the reaction proceeded, new equilibrium reached to generate the ring-opened form **3'** and can undergo further alkylation at the phenolic OH to give the product **5** as the major product. In the reaction, compound **4** was also formed as the minor product via **B**. The formation of **4** has been explained by using the concept of "transfer of nucleophilicity" as depicted in Scheme 1.<sup>1a</sup>

Recently we have published a facile synthetic method of benzo[b]indeno[2.1-d]furanone skeleton from the reaction of ninhydrin and cyclohexane-1,3-diones.<sup>3</sup> During the oxidative aromatization reaction of the intermediate with iodine in methanol we have found that the hydroxyl group at the hemiketal portion can be selectively converted into methoxy group to some extent.<sup>3</sup>

In these respects, we envisioned that we might control the alkylation position for the ninhydrin-phenol adducts **3** (Scheme 1). Currently we are interested in the synthesis of various types of alkylated or acylated benzo[b]indeno[2,1-d]furanone systems in order to examine their antiviral activities.<sup>4</sup> Actually, some compounds showed high antiviral





Figure 1. <sup>1</sup>H NMR spectra of ninhydrin-phenol adduct **3a** in  $CDCl_3$  (a),  $DMSO-d_6$  (b), and  $DMSO-d_6-D_2O$  (c). The peaks marked with asterisk are derived from **3a**'.

activity against coxsackie A, coxsackie B, echovirus, and poliovirus in a 0.04-0.09  $\mu$ g/mL level. Thus, in this paper we wish to report the selective methylation at the hemiketal portion of ninhydrin-phenol adducts.


The reaction of 3a and iodine (2.0 equiv.) in methanol gave the methylated compound 4a in 56% yield. As expected, desired compounds 4b-e were prepared in good to moderate yields (47-77%) with iodine in methanol or ethanol from 3b-d, which could be easily prepared from the reaction of ninhydrin and *p*-cresol, *m*-cresol, and hydroquinone, respectively. For the *m*-cresol derivative 3c, iodination at the aryl moiety occurred (entry 3) to give 6 to some extent. When we used ethanol in the reaction, ethylated

<sup>&</sup>lt;sup>•</sup>Corresponding author. Phone: +82-62-530-3381, e-mail: kimjn @chonnam.ac.kr



Scheme 1

Table 1. Selective alkylation at the hemiketal position of ninhydrin-phenol adducts 3



Notes

compound 4e was synthesized in 51% yield (entry 5). The reaction mechanism for the formation of 4 was depicted in Scheme 1: electrophilic iodination,<sup>3,5</sup> formation of cyclic oxonium ion intermediate, and addition of methanol to give the corresponding methylated compounds  $4.^{3,5}$  The structure including the regiochemistry and the relative stereochemistry of the OH and methoxy group (*cis* relationship) of 4b were confirmed by NOE experiment.<sup>6</sup>

In summary, we have synthesized the alkylated compounds at the hemiketal part of ninhydrin-phenol adducts selectively by using the iodine-alcohol system.

## **Experimental Section**

Typical procedure for the synthesis of the starting material 3a: A mixture of ninhydrin (356 mg. 2 mmol) and phenol (188 mg, 2 mmol) in acetic acid (5 mL) was heated to reflux for 3 h. After usual aqueous workup procedure and column chromatographic purification process (hexanes/ether. 1 : 1), desired ninhydrin-phenol adduct 3a was obtained in 63% yield (320 mg). Other starting materials 3b-d have been synthesized analogously and the spectroscopic data are summarized below.

Typical procedure for the selective methylation of 3a: To a stirred solution of 3a (254 mg, 1 mmol) in dry methanol (5 mL) was added iodine (508 mg, 2 mmol) and the reaction mixture was heated to reflux for 19 h. After removal of the solvent and purification by flash column chromatography (hexanes/ether, 2:1) we obtained the desired compound 4a in 56% yield (150 mg). Other products 4b-e and 6 have been synthesized similarly and the spectroscopic data are summarized below.

**3a** (63%): mp 166-168 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  3.94 (s. 1H), 4.72 (s, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.78-7.82 (m, 2H), 8.02 (d, J = 7.8 Hz, 1H).

**3b** (63%): mp 160-162 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.25 (s. 3H), 3.93 (s. 1H), 4.74 (s. 1H), 6.73 (d. *J* = 8.3 Hz, 1H), 7.06 (t. *J* = 8.3 Hz, 1H), 7.29 (s. 1H), 7.57 (t. *J* = 7.1 Hz, 1H), 7.77-7.81 (m, 2H), 8.00 (d. *J* = 6.9 Hz, 1H).

**3c** (78%): mp 162-164 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.26 (s. 3H), 4.35 (s. 1H), 5.00 (s. 1H), 6.62 (s. 1H), 6.75 (d. *J* = 7.4 Hz, 1H), 7.35 (d. *J* = 7.8 Hz, 1H), 7.53 (t. *J* = 7.8 Hz, 1H), 7.74-7.82 (m, 2H), 7.99 (d. *J* = 7.8 Hz, 1H).

**3d** (65%): mp 215-216 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub> + 1 drop of DMSO-d<sub>6</sub>)  $\delta$  5.97 (s. 1H), 6.60 (d. *J* = 8.7 Hz, 1H), 6.71 (s. 1H), 6.74 (d. *J* = 8.7 Hz, 1H), 7.06 (s. 1H), 7.53 (t. *J* = 7.5 Hz, 1H), 7.73-7.81 (m, 2H), 7.96 (d. *J* = 7.8 Hz, 1H), 8.62 (s. 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub> + 1 drop of DMSO-d<sub>6</sub>)  $\delta$  83.18, 109.83, 110.57, 111.88, 118.80, 123.27, 125.01, 125.54, 130.55, 134.53, 136.29, 149.22, 149.97, 152.21, 198.73.

4a (56%): mp 152-154 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  3.49 (s. 1H), 3.76 (s. 3H), 6.87 (d. *J* = 8.4 Hz, 1H), 7.00 (t. *J* = 7.5 Hz, 1H), 7.25-7.32 (m. 1H), 7.52-7.60 (m. 2H), 7.76-7.83 (m. 2H), 7.93 (d. *J* = 7.5 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  53.57, 83.41, 110.83, 111.71, 122.28, 124.08, 125.03,

125.10, 125.68, 131.28, 131.93, 134.63, 136.54, 147.70, 157.70, 198.96; Mass (70 eV) *m*<sup>2</sup> (rel intensity) 76 (9), 104 (6), 121 (8), 152 (9), 181 (4), 208 (28), 225 (35), 236 (100), 268 (M<sup>+</sup>, 5).

**4b** (77%): mp 176-178 °C: <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.28 (s, 3H). 3.43 (s. 1H), 3.75 (s, 3H). 6.75 (d. *J* = 8.4 Hz. 1H), 7.08 (d. *J* = 8.4 Hz. 1H), 7.33 (s, 1H). 7.55 (t. *J* = 7.8 Hz. 1H), 7.75-7.82 (m. 2H). 7.92 (d. *J* = 7.8 Hz, 1H): Mass 77 (11), 165 (12), 222 (20), 239 (52), 250 (100). 282 (M<sup>-</sup>, 15).

**4c** (47%): <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.30 (s, 3H), 3.50 (s, 1H), 3.76 (s, 3H). 6.68 (s, 1H). 6.81 (d, *J* = 7.8 Hz, 1H). 7.40 (d, *J* = 7.8 Hz, 1H), 7.56 (t, *J* = 7.2 Hz. 1H). 7.76-7.81 (m, 2H), 7.92 (d, *J* = 7.2 Hz. 1H).

4d (63%): mp 155-156 °C: <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  3.41 (s, 1H). 3.75 (s. 3H), 3.76 (s. 3H), 6.77 (d. *J* = 9 Hz, 1H). 6.86 (d. *J* = 8.8 Hz. 1H), 7.05 (s, 1H). 7.57 (t. *J* = 7.5 Hz. 1H), 7.78-7.83 (m. 2H), 7.92 (d. *J* = 8.0 Hz, 1H): <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  53.48. 55.96. 84.26, 108.47. 111.43. 111.78, 119.31, 124.02. 125.08, 125.63, 131.22. 134.56. 136.52. 147.77, 151.07. 155.26, 198.89.

4e (51%): <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.29 (t. J = 6.7 Hz, 3H), 1.36 (t, J = 6.7 Hz, 3H), 3.59 (s. 1H), 3.92-4.12 (m. 4H), 6.74 (d. J = 8.8 Hz. 1H), 6.84 (d, J = 8.9 Hz, 1H), 7.05 (s, 1H), 7.55 (t. J = 7.4 Hz. 1H), 7.76-7.81 (m, 2H), 7.92 (d. J =7.4 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  14.80, 15.66, 61.93, 64.27, 84.07, 109.38, 111.29, 111.84, 119.77, 123.94, 125.07, 125.62, 131.08, 134.52, 136.46, 148.06, 151.00, 154.49, 199.04.

**6** (28%): <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.36 (s, 3H). 3.48 (s. 1H), 3.76 (s. 3H), 6.80 (s, 1H). 7.59 (t. *J* = 7.5 Hz. 1H). 7.78-7.83 (m. 2H). 7.90-7.93 (m. 2H): <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  28.80, 53.67, 83.21. 90.82. 112.18, 112.26, 124.15. 124.76. 125.61, 131.45, 134.36. 134.75, 136.69, 145.31. 147.36. 157.32, 198.55.

Acknowledgments. This study was financially supported by research fund of Chonnam National University in 2003. Spectroscopic data were obtained from the Korea Basic Science Institute. Gwangju branch.

## References and Notes

- (a) Song, H. N.; Seong, M. R.; Lee, H. J.; Kim, J. N. Synth. Commun. 1999, 29, 2759. (b) Song, H. N.; Kim, H. S.; Kim, J. N. Bull, Korean Chem. Soc. 1999, 20, 631.
- The benzo[b]indeno[2.1-d]furanone skeleton have been known in some references, see: (a) Bullington, J. L.; Dodd, J. H. J. Org. Chem. 1993, 58, 4833. (b) Roth, H. J.: Kok, W. Arch. Pharmaz. 1976. 309, 81. (c) Poupelin, J.-P.; Saint-Ruf, G.; Perche, J.-C.; Roussey, J.-C.; Laude, B.; Narcisse, G.; Bakri-Logeais, F.; Hubert, F. Eur. J. Med. Chem. 1980, 15, 253. (d) Poupelin, J.-P.; Saint-Ruf, G.; Perche, J.-C.; Lacroix, R.; Uchida-Emouf, G.; Narcisse, G.; Hubert, F. Eur. J. Med. Chem. 1979, 14, 171.
- (a) Na, J. E.; Kim, J. M.; Lee, S.; Kim, J. N. Bull. Korean Chem. Soc. 2003, 24, 1725. For our recent publications on the application of iodine in methanol system, see: (b) Kim, J. M.; Lee, K. Y.; Kim, J. N. Bull. Korean Chem. Soc. 2003, 24, 1057. (c) Kim, J. M.; Lee, K. Y.; Kim, T. H.; Kim, J. N. Bull. Korean Chem. Soc. 2003, 24, 999. (d) Kim, J. M.; Na, J. E.; Kim, J. N. Tetrahedron Lett. 2003, 44, 6317.
- 4. Unpublished results. The antiviral activities of the prepared

compounds will be published in due course. For the biological activities of similar compounds, see: (a) Mertens, A.; Zilch, H.; Konig, B.; Schafer, W.; Poll, T.; Kampe, W.; Seidel, H.; Leser, U.; Leinert, H. *J. Med. Chem.* **1993**, *36*, 2526. (b) Schafer, W.; Friebe, W.-G.; Leinert, H.; Mertens, A.; Poll, T.; von der Saal, W.; Ailch, H.; Nuber, B.; Ziegler, M. L. *J. Med. Chem.* **1993**, *36*, 726.

5. (a) Verhart, C. G. J.; Fransen, C. T. M.: Zwanenburg, B.:

Chittenden, G. J. F. *Recl. Trav. Chim. Pays-Bas.* **1996**, *115*, 133. (b) Rutherford, K.: Mamer, O.: Prokipcak, J.: Jobin, R. Can. J. Chem. **1966**, *44*, 2337. (c) Jennep, G. *Tetrahedron Lett.* **1988**, *29*, 2455.

6. When we irradiate the OH proton signal ( $\delta$ = 3.43 ppm), the methoxy group ( $\delta$ = 3.75 ppm) and the aromatic singlet proton ( $\delta$  = 7.33 ppm) showed 0.5% and 0.3% NOE increments, respectively.